Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Study of Ketamine for Youth Depression

To see complete record on, please visit this link

Id: ACTRN12619000683134

Organisation Name: Orygen, the National Centre of Excellence in Youth Mental Health

Overal Status: Suspended

Start Date: 20/05/2019

Brief Summary: The primary aim of this research project is to determine if a 4-week course of low-dose subcutaneous ketamine is an effective treatment for young people
(males and females aged 16-25 years) with moderate-to-severe depression. Participants will be randomised to receive either low-dose subcutaneous ketamine or a blinded control treatment that is therapeutically inactive (midazolam), given once a week for 4 weeks. Change in depression scores will be assessed at the end of the treatment phase at week 4, with further assessment at weeks 8 and 26 to assess whether treatment effects are sustained. We hypothesise that ketamine will be an effective treatment for moderate-to-severe depression in young people.

  • Australia

Total execution time in seconds: 0.16338896751404